

Table 1. Baseline characteristics of included patients.

Characteristic		Rectal cancer cohort (n=8)	Pancreas cancer cohort (n=9)
Age	Median (yrs)	64	64
	IQR (yrs)	59.5 – 65.5	59 - 70
Gender female n (%)		4 (50%)	3 (33.3%)
ECOG n (%)	0	1 (12.5%)	2 (22.2%)
	1	7 (87.5%)	6 (66.7%)
	N.R.	0 (0%)	1 (11.1%)
DM n (%)		3 (37.5%)	4 (44.4%)
Stage at enrolment n (%)	1	0 (0%)	0 (0%)
	2	2 (25%)	0 (0%)
	3	4 (50%)	2 (22.2%)
	4	2 (25%)	7 (77.8%)
Therapy prior to CXCR4-PET n (%)	Chemo	2 (25%)	3 (33.3%)
	XRT	1 (12.5%)	0 (0%)
	Surgery	0 (0%)	0 (0%)
Biopsy-confirmed malignancy n (%)		8 (100%)	9 (100%)
Had CXCR4-PET n (%)		8 (100%)	9 (100%)
AE recorded secondary to Pentixafor-PET (any grade) n (%)		0 (0%)	0 (0%)
Had FDG-PET n (%)		4 (50%)*	9 (100%)

IQR: Interquartile range; yrs: years; ECOG: Eastern Cooperative Oncology Group Performance Status; DM: Diabetes mellitus; AE: Adverse event. FDG-PET: Fluorodeoxyglucose positron emission tomography